With more than €2 billion invested across our global network, we are expanding both commercial and clinical manufacturing capacity to help our customers accelerate development, scale production, and secure reliable supply throughout the product lifecycle.
To support growing commercial demand, we are substantially increasing our aseptic manufacturing and packaging capabilities in Europe. Our newest commercial manufacturing site strengthens our global production network and provides additional capacity for large-scale supply.
Key investments include:
These investments enable greater manufacturing flexibility and provide customers with enhanced capacity for future commercial success.
Supporting emerging therapies requires reliable and scalable clinical manufacturing infrastructure. To meet increasing demand from biotech innovators, we continue to expand our clinical manufacturing capabilities.
Key investments include:
